BaliBabyDoc
Lifer
- Jan 20, 2001
- 10,737
- 0
- 0
Price controls may or may not affect this problem
Some that growth reflects increasing use for approved ailments (epilepsy) but much of it came from diabetic neuropathy, migraines, chronic pain syndromes, and bipolar.
Sounds like Boiler Room or Wall Street.
''I was trained to do things and did things that were blatantly illegal,'' Franklin, 41, said during an interview at the Boston office of his attorney, Thomas Greene. ''I knew my job was to falsely gain physicians' trust and trade on my graduate degree. If he was a cardiologist, I was an expert in cardiology. If he was a neurologist I was an expert in neurology.''
In Massachusetts alone, Medicaid spending on Neurontin grew from $1.1 million in 1996 to $14.1 million in 2000, the height of the Parke-Davis marketing campaign.
Some that growth reflects increasing use for approved ailments (epilepsy) but much of it came from diabetic neuropathy, migraines, chronic pain syndromes, and bipolar.
''I'd tell them we had physicians across the county, some involved in clinical trials, and others who had hundreds of patients on Neurontin, all getting an extraordinary response rate,'' Franklin said. ''We'd make them think everyone was using it but them.''
During training sessions, he said, managers explained how to ''enable'' a physician to prescribe Neurontin for off-label uses by suggesting specific doses, and how to ''close'' the doctor by asking him to put his next patient with bipolar illness or some other condition on Neurontin.Franklin said Parke-Davis executives believed representatives at other pharmaceutical companies engaged in similar practices. ''We weren't on par with them in terms of the size of our sales force,'' he said. ''But there was a belief that much of what we were doing was typical. We were driving 60 miles per hour in a 55 mile per hour zone. Everyone did it.''
Sounds like Boiler Room or Wall Street.
